

Wednesday Evening 22nd February 2017

IACR Junior Council and Outreach Session (Wednesday Evening)

- 17.00-17.30** **Finger Food Reception/ Meet and greet**
- 17.30-18.30** **Session 1: Careers and Recruitment Session**
(Chaired by Maria Prencipe and Maeve Kiely)
- 17.30** **Ms. Naoimh O'Connor**, (Research Careers Manager, University College Dublin)
'The Post-PhD Job-seeking Strategy'
- 17.45** **Mr. Oisín O'Diomasaigh**
(Graduate Advice Program Manager Life Science Consultants)
'Unravelling your career path- Looking at the Pharma/Biotech sector and using the 5Ws Where/What/Why/When/who.'
- 18.00** **Dr Linda Nolan** (Managing Director MyBio Ltd)
'The transition from Ph.D student to business owner.'
- 18.15-18.30** **Panel Discussion Q&A**
- 18.30-19.30** **Session 2. Grant Writing and Science Communication Session**
(Chaired by Denis Collins and Sara Charmsaz)
- 18.30** **Mr Sean Duke** (Science Journalist, Broadcaster, Author)
'Why Science Communication matters'.
- 18.45** **Prof Chris Scott** (Chair of Pharmaceutical Biosciences), Queens University Belfast
'Conducting commercially relevant research in academia - walking the tightrope'
- 19.00** **Dr Elaine Dunleavy** (SFI-PIYRA Awardee NUI Galway)
'My experience as a SFI-HRB-Wellcome Trust Career Development Fellow'
- 19.15-19.30** **Panel Discussion Q&A**

KINDLY SPONSORED BY:

Thursday 23rd February 2017
IACR Scientific Sessions

- 09.00 - 09.15: **Welcome Address: Prof William Watson (IACR President)**
- 09.15 -10.15: **PROFFERED PAPER 1 SESSION (selected from Abstract Submissions)**
(Chaired by Dr Eva Szegezdi and Marion Butler)
4 x 15 minute presentations (12 mins + 3 mins Q&A)
- 09.15-09.30 **IDENTIFICATION AND CHARACTERISATION OF NOVEL RACK1 BINDING PARTNERS THAT MAY MODULATE THE ELONGATION PHASE OF PROTEIN SYNTHESIS.**
Beatrice Malacrida^{1,2}, RK Flygaard³, CM Dowling^{1,2}, JC Coffey¹, LB Jenner³, PA Kiely^{1,2},
¹Graduate Entry Medical School, University of Limerick, ²Health Research Institute , University of Limerick, ³Department of Molecular Biology and Genetics, Aarhus University, Aarhus
- 09.30-09.45 **FKBPL AS A NOVEL PROGNOSTIC BIOMARKER AND THERAPEUTIC AGENT IN HIGH GRADE SEROUS OVARIAN CANCER**
Stephanie L Annett^{1,2}, L McClement¹, HO McCarthy¹, F Furlong¹, I Harley³, G McCluggage³, T Robson^{1,2},
¹Molecular and Cellular Therapeutics , Royal College of Surgeons, Dublin
²School of Pharmacy, Queen's University Belfast, ³, Belfast Health of Social Care Trust, Belfast
- 09.45-10.00 **IDENTIFICATION OF SPLICEOSOMAL COMPONENTS AS NOVEL THERAPEUTIC TARGETS FOR THE THERAPY OF CHILDREN WITH HIGH-RISK MYCN-AMPLIFIED NEUROBLASTOMA**
Melinda Halasz^{1,2}, T Santra¹, S Furney³, D Fey¹, K Iljin⁴, M Fischer⁵, F Westermann⁶, AT Look⁷, W Kolch^{1,2,3}
¹Systems Biology Ireland, University College Dublin, ²School of Medicine, University College Dublin, ³Conway Institute, University College Dublin, ⁴, VTT Technical Research Centre of Finland, Espoo, ⁵Department of Paediatric Haematology and Oncology , University Hospital Cologne, Cologne, ⁶German Cancer Research Centre, Heidelberg, ⁷Dana-Farber Cancer Institute, Boston
- 10.00-10.15 **STROMAL CELL IMMUNOMODULATORY POTENTIAL IN THE TUMOUR MICROENVIRONMENT IS REGULATED BY INFLAMMATORY SIGNALLING**
Grace O'Malley^{1,2}, SD Naicker², K Lynch², P Lohan², A Rigalou^{1,2}, T Ritter², LJ Egan¹, AE Ryan^{1,2}
¹Pharmacology and Therapeutics, NUI Galway, Galway
²Regenerative Medicine Institute (REMEDI), College of Medicine, NUI Galway, Galway
- 10.15-10.30: **Gold Sponsor Presentation – Pfizer**
“Development of an anti-P-cadherin/ anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer”
Brian Fennell - BioMedicine Design (BMD), Pfizer
- 10.30-11.00: **Tea/Coffee/Posters & Meet the Sponsors**

- 11.00-12.30: **PLENARY SESSION 1: TARGETING TRANSCRIPTIONAL DE-REGULATION IN CANCER**
(Chaired by Dr Triona NiChonghaile and Dr Simon McDade)
- 11.00-11.30 **‘DRIVERS’ AND ‘FEEDBACK LOOPS’ IN PROSTATE CANCER CELLS**
Dr Ian Mills, Reader, Queens University Belfast
- 11.30-12.00 **THE IMPACT OF CELLULAR AGE ON LEUKAEMIC TRANSFORMATION**
Dr Karen Keeshan, Reader, Paul O’Gorman Leukaemia Research Centre
College of Medicine, Veterinary & Life Sciences
(University of Glasgow)
- 12.00-12.30 **ACQUIRED CYP19A1 AMPLIFICATION IS AN EARLY SPECIFIC MECHANISM OF
AROMATASE INHIBITOR RESISTANCE IN ERA METASTATIC BREAST CANCER**
Dr Luca Magnani, Imperial College London
- 12.30-13.00 **‘SATELLITE SESSION’ WITH NEXCELOM (Main Auditorium)**
*“A Rapid High-Throughput 3D Tumor Spheroid Imaging Cytometry Screening
Method for Drug Discovery”*
Scott Cribbes, Director of Applications and Emerging Technologies, Nexcelom
- 13.00-14.00 **LUNCH, TRADE EXHIBITION AND POSTER VIEWING**
IACR JUNIOR COUNCIL NETWORKING LUNCH
- 14.00-16.00: **PLENARY SESSION 2: CHALLENGES IN CHILDHOOD CANCERS**
(Chaired by Dr Olga Piskarvea and Dr Graham Pidgeon)
- 14.00-14.30 **ORIGIN, EVOLUTION AND TARGETING OF CHILDHOOD LEUKAEMIA**
Professor Tariq Enver, UCL Cancer Institute, London
- 14.30-15.00 **THE PROMISE AND CHALLENGE OF NUCLEIC ACIDS AS CIRCULATING BIOMARKERS
FOR RISK STRATIFICATION AND ADAPTIVE CANCER TREATMENT IN CHILDREN
WITH NEUROBLASTOMA**
Prof. Sue Burchill, Leeds Institute of Cancer and Pathology, UK.
- 15.00-15.30 **IMPACT OF TRISOMY 21 ON HAEMATOPOIESIS AND LEUKAEMIA IN EARLY LIFE**
Prof. Irene Roberts, Department of Paediatrics and MRC Molecular Haematology
Unit, Weatherall Institute of Molecular Medicine, University of Oxford, UK
- 15.30-16.00 **MODULATING THE NEUROBLASTOMA PHENOTYPE WITH EPIGENETICALLY
REGULATED microRNA**
Prof. Raymond Stallings, Director of Research & Innovation, RCSI Office of Research
and Innovation Royal College of Surgeons in Ireland
- 16.00-16.40: **ORAL POSTER PRESENTATIONS (Prof. John Fitzpatrick Medal)**
(Chaired by Dr Antoinette Perry and Dr Mark Tangney)
(6 x 6 minute presentations, selected from Abstract Submissions)
- 16.00-16.06 **PRIMARY CULTURES OF PANCREATIC CANCER PATIENT DERIVED XENOGRAPHS TO
MODEL CHEMOTHERAPEUTIC RESPONSE**
Sandra Roche¹, V Guinot¹, F O’Neill¹, N Swan², N Lopez-Straubinger³, J Murphy², K
Conlon², J Geoghegan², R McDermott², J Meiller¹, R O’Connor¹, M Moriarty^{1,2}, M
Clynes¹, RM Staubinger³, N Barron¹
¹National Institute for Cellular Biotechnology, Dublin City University, Dublin 9
², St Vincent’s University Hospital, Dublin 4
³Department of Pharmaceutical Sciences, , University at Buffalo, State University of
New York, Buffalo, New York

- 16.06-16.12 **THE AMP-KINASE PROTEIN AS A POTENTIAL THERAPEUTIC TARGET IN COLORECTAL CANCER**
Ciara C Dunphy^{1,2}, A O' Brien^{1,2}, H Dussmann^{1,2}, J Lopez³, S Tait³, SL Pfeiffer^{1,2}, JHM Prehn^{1,2,1}Centre for Systems Medicine, Royal College of Surgeons Ireland, Dublin
²Physiology and Medical Physics, University of Glasgow, Glasgow
³The Beatson Institute for Cancer Research, University of Glasgow, Glasgow
- 16.12-16.18 **TACKLING ACQUIRED RESISTANCE MECHANISMS IN MALIGNANT MELANOMA**
C Fitzgibbon¹, E Chiquero-Leon¹, Z Liu¹, N Rauch¹, E Panada¹, A von Kriegsheim¹, W Kolch^{1,2}, **Jens Rauch**
¹Systems Biology Ireland, University College Dublin, ²Conway Institute, University College Dublin, Dublin
- 16.18-16.24 **CONTRIBUTION OF IRE1 SIGNALING TO THE PROGRESSION OF TRIPLE NEGATIVE BREAST CANCER**
Susan E Logue¹, P Cleary¹, E McGrath¹, K Mnich¹, A Samali¹
¹Apoptosis Research Centre, School of Natural Sciences, National University of Ireland Galway, Galway
- 16.24-16.30 **NOVEL SDC2-FC PEPTIDES ATTENUATE TGFB, CXCR4 AND PD-L1 SIGNALLING IN BREAST CANCER STROMA.**
Paul Loftus¹, L Watson¹, L Deedigan¹, L O'Flynn¹, M Kerin², T O'Brien³, S Elliman¹, LR Barkley⁴
¹Orbsen Therapeutics, National University of Ireland, ²Lambe Institute, National University of Ireland, ³REMEDI, National University of Ireland, ⁴National University of Ireland, Galway
- 16.30-16.36 **EMPLOYING MESENCHYMAL STEM CELLS AS TUMOUR-TARGETED DELIVERY VEHICLES OF EXOSOMAL microRNA-379**
Killian P O'Brien¹, K Gilligan¹, S Khan¹, B Moloney¹, K Thompson², P Lalor², P Dockery², H Ingoldsby³, MJ Kerin¹, RM Dwyer¹
¹Discipline of Surgery, School of Medicine, National University of Ireland, Galway, ²Discipline of Anatomy, School of Medicine, National University of Ireland, Galway, ³Discipline of Pathology, School of Medicine, National University of Ireland, Galway, Galway
- 16.40-16.55: **Gold Sponsor Presentation – Nanostring**
3D Biology Technology: DNA, RNA and Protein
Ajay Johni, Nanostring Technologies
- 16.55- 17.30: **Tea/Coffee/Posters & Meet the Sponsors**
- 17.30-18.30: **IRISH CANCER SOCIETY SCHOLAR AND FELLOW PRESENTATIONS**
(The highest scoring abstracts from 2 x ICS funded PhD students and 2 x ICS funded Postdocs will be selected for presentation)
(Chairs: Dr Naomi Walsh and Dr Isabella Bray)
- 17.30-17.45 **(PhD)** **RNA SEQUENCING IDENTIFIES BROMODOMAIN PROTEINS AS A THERAPEUTIC STRATEGY FOR INVASIVE LOBULAR CARCINOMA**
Louise Walsh¹, B Moran², S Das¹, F Tarrant², Y Fan², P Schouten³, S Chin⁴, S Linn³, R Bernards⁵, C Caldas⁴, WM Gallagher², T Ní Chonghaile*⁶, DP O'Connor*¹
¹Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, ²School of Biomolecular and Biomedical Science, University College Dublin, ³Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, ⁴Cancer Research UK Cambridge institute, University of Cambridge, Cambridge, ⁵Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, ⁶Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin

- 17.45-18.00 **EXPRESSION OF THE COCAINE- AND AMPHETAMINE-REGULATED TRANSCRIPT (CART) RECRUITS BAF CHROMATIN REMODELLING COMPLEXES TO THE ESTROGEN RECEPTOR**
(PhD)
Brian P Mooney¹, S Das¹, R Klinger², B Moran², E Conway³, B Doyle², K Wynne², WM Gallagher², T Ni Chonghaile⁴, G Cagney², AP Bracken³, DP O'Connor¹
¹Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin
²School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin, ³Smurfit Institute of Genetics, Trinity College Dublin, Dublin
⁴Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin
- 18.00-18.15 **AROMATASE INHIBITOR REPURPOSING FOR THE TREATMENT OF AN AGGRESSIVE BRAIN CANCER, GLIOBLASTOMA, USING ANTI-GD2-CH14.18/CHO COATED BIODEGRADABLE NANOPARTICLES.**
(Postdoc)
Amanda Tivnan¹, H Heilinger^{1,2}, JM Ramsey³, G O'Connor³, JL Pokorny^{4,5}, JN Sarkaria⁵, BW Stringer⁶, BW Day⁶, Boyd AW⁶, EL Kim⁷, HN Lode⁸, SA Cryan³, JHM Prehn¹
¹Centre for Systems Medicine, Department of Physiology and Medical Physics, The Royal College of Surgeons in Ireland, Dublin, ²IMC Fachhochschule KREMS, University of Applied Sciences, KREMS, Austria, ³School of Pharmacy & Tissue Engineering Research Group, Dept Anatomy, RCSI & Centre for Research in Medical Devices (CURAM), NUIG., Dublin, ⁴Dept of Radiation, Mayo Clinic, Rochester, MN, ⁵Centre for Mind and Brain, University of California, Davis, California, ⁶Brain Cancer Research Unit, QIMR Berghofer Medical Research Institute, Brisbane, ⁷Department of Neurooncology, Johannes Gutenberg University Medical Center, Mainz, Germany, ⁸Department of Paediatrics and Paediatric Haematology/Oncology, University of Greifswald, Greifswald, Germany
- 18.15-18.30 **MECHANISTIC INTERROGATION OF PRE-TREATMENT LOW DOSE ASPIRIN EFFECTS IN HER 2 POSITIVE BREAST CANCER**
(Postdoc)
Ian S Miller¹, S Khan², S Das³, LP Shiels⁴, B Moran⁴, FP Leacy⁵, PL Loadman⁶, RS Kerbel⁵, D O'Connor³, K Bennett⁸, RM Dywer², AT Byrne¹
¹Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin ² Department of Surgery and REMEDI, National University of Ireland, Galway, Galway ³Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, ⁴Conway Institute of Biomedical and Biomolecular Science, University College Dublin, Dublin, ⁵Biostatistics Core, Royal College of Surgeons in Ireland, ⁶Department of Chemistry, University of Bradford, Bradford, UK, ⁷Sunnybrook Institute, University of Toronto, Toronto, Canada, ⁸Dept of Population and Health Science , Royal College of Surgeons in Ireland, Dublin
- 18.30-18.45: **Short address from Dr Robert O'Connor (The Irish Cancer Society)**
- 18.45-19.45: **IRISH CANCER SOCIETY LECTURE**
"DELIVERING PRECISION MEDICINE FOR MELANOMA"
Professor Richard Marais, Director
Cancer Research UK Manchester Institute
- 19.45–22.30: **FORMAL POSTER SESSION**
19.45-20.30: Buffet Dinner and Wine Reception
20.30-21.30: TRADE EXHIBITION/ /Presentation of odd Poster Numbers
21.30-22.30: TRADE EXHIBITION/ **Coffee and Dessert**/Presentation of even Poster Numbers

Friday 24th February 2017 - IACR Scientific Sessions

- 08.00-09.00: **Junior Council Networking Breakfast**
- 09.00-10.30: **PLENARY SESSION 3: “TRANSLATING QUESTIONS INTO TREATMENTS FOR PATIENTS”**
(Chaired by Professor William Watson and Dr Norma O’Donovan)
“NEW USES FOR AN OLD DRUG IN MULTIPLE MYELOMA”
Janusz Krawczyk, Senior Lecturer in Haematology and Cellular Therapy, Blood Cancer Network, Galway
- TCHL: A PHASE II NEO-ADJUVANT STUDY ASSESSING TCH (DOCETAXEL, CARBOPLATIN AND TRASTUZUMAB AND TCHL (DOCETAXEL, CARBOPLATIN, TRASTUZUMAB AND LAPATINIB) IN HER-2 POSITIVE BREAST CANCER PATIENTS**
Giuseppe Gullo, Consultant Medical Oncologist, St. Vincent’s University Hospital, Dublin
- ‘IDENTIFYING EARLY PROGNOSTIC MARKERS OF PATHOLOGICAL COMPLETE RESPONSE (PCR) IN NEOADJUVANT TCHL TREATED HER2-POSITIVE BREAST CANCER AND STUDYING THE IMPACT OF TCHL BASED THERAPY ON THE MOLECULAR EVOLUTION OF HER2-POSITIVE BREAST CANCER.’**
Alex Eustace PhD, HRB Post-Doctoral Researcher, RCSI PGHPE 1
Royal College of Surgeons in Ireland, RCSI Education & Research Centre, Beaumont Hospital, Beaumont, Dublin 9
- “CREATING AN ABCOPAL EFFECT: FROM OBSERVATION TO DESIGN”**
Declan Soden and Derek Power
- 10.30-10.45: **Gold Sponsor Presentation – Philips Digital Pathology Solutions**
Integrating Computational Pathology and Tissue Analytics for Molecular Pathology
Eileen Regan, (Key Account Manager, Philips Digital Pathology Solutions, Royal Philips)
- 10.45-11.15: **TEA/COFFEE/POSTERS & MEET THE SPONSORS**
- 11.15-11.30: ***Cancer Research to Impact Cancer Care***
Orla Dolan, Head of Fundraising, Breakthrough Cancer Research
- 11.30-12.30: **PROFFERED PAPER 2 SESSION**
4 x 15 minute presentations (12 mins + 3 mins Q&A)
(Chaired by Dr Niamh Buckley and Dr Tara Dalton)
- 11.30-11.45 **HIGH CDK7 IS LINKED TO POOR OUTCOME IN TRIPLE-NEGATIVE BREAST CANCER AND IS A RATIONAL THERAPEUTIC TARGET**
B Li¹, T Ni Chonghaile², Y Fan¹, SF Madden³, R Kinger¹, AE O’Connor¹, G O’Hurley⁴, GM Udipi⁴, J Joseph⁴, F Tarrant¹, E Conroy¹, A Gaber⁵, SF Chin⁶, HA Bardwell⁶, E Provenzano⁷, T Dubois⁸, S Linn⁹, C Caldas⁶, DP O’Connor¹⁰, WM Gallagher^{1,4}
¹School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, ²Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, Dublin, ³Population Health Sciences Division, Royal College of Surgeons in Ireland, Dublin, ⁴OncoMark Ltd, Belfield Innovation Park, Dublin ⁵Faculty of Medicine, Lund University, Lund, ⁶Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, ⁷Cambridge Experimental Cancer Medicine Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, ⁸Department of Translational Research, Breast Cancer Biology Group, Institut Curie, Paris, ⁹Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, ¹⁰Department of Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, ¹⁹Department of Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin

- 11.45-12.00 **A HIGH-THROUGHPUT SCREEN IDENTIFIED CANCER SELECTIVE SMALL MOLECULES THAT KILL INDEPENDENT OF MITOCHONDRIAL APOPTOSIS**
Catriona M Dowling¹, M Hemann², J Bradner³, A Letai⁴, T Ni Chonghaile¹
¹Department of Physiology and Medical Physics, Royal College of Surgeons , Dublin
²Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, ³Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, ⁴Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
- 12.00-12.15 **CancerGD: A RESOURCE FOR IDENTIFYING AND INTERPRETING GENETIC DEPENDENCIES IN CANCER**
 S Bridgett¹, J Campbell², C.J. Lord², **Colm J. Ryan**¹
¹Systems Biology Ireland, University College Dublin, ² The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, ³Helen Diller Family Comprehensive Cancer Centre, University of California, San Francisco, San Francisco
- 12.15-12.30 **A NOVEL ROLE FOR THE COMPLEMENT SYSTEM IN RADIORESISTANT OESOPHAGEAL ADENOCARCINO**
Niamh Lynam-Lennon¹, D Lavin¹, R Byrne¹, JV Reynolds¹, J O'Sullivan¹
¹Department of Surgery, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin
- 12.30-12.45 **Gold Sponsor Presentation – Agilent Technologies**
Providing Future Solutions For Cellular Bioenergetics And Metabolomics Studies
Alex Liversage, Agilent Technologies
- 12.45-13.050 **IACR AGM**
- 13.05-14.05: **Lunch, Trade Exhibitions and Poster viewing**
- 14.05-15.35: **PLENARY SESSION 4: ADVANCED MOUSE MODELS IN CANCER (Chaired by Dr Brona Murphy and Dr Ken Nally)**
- 14.05-14.35 **INTERROGATING OPEN ISSUES IN CANCER PRECISION MEDICINE USING PATIENT-DERIVED XENOGRAFTS**
Dr Annette Byrne, Snr Lecturer, Academic Director for Curriculum Mapping, Royal College of Surgeons in Ireland
- 14.35-15.05 **CANCER EVOLUTION AS A THERAPEUTIC TARGET**
Professor Alberto Bardelli, Dept. of Oncology, University of Torino, Director of the Laboratory of Molecular Oncology and Deputy Director of the Candiolo Cancer Institute-IRCCS, Torino, Italy.
- 15.05-15.35 **PATIENT-DERIVED XENOGRAFTS EFFECTIVELY CAPTURE RESPONSES TO ONCOLOGY THERAPY IN PATIENTS WITH SOLID TUMORS**
David Sidransky MD, Johns Hopkins University, Baltimore, MD 21215
- 15.35-16.00: **Tea/Coffee/Posters & Meet the Sponsors**

- 16.00-17.00: **EACR YOUNG SCIENTIST AWARDS**
(2 x 25 mins + 5 mins Q&A)
Chairs: Professor Alberto Bardelli (President Elect of the EACR) and Professor Amanda McCann (President Elect of the IACR)
- 16.00-16.30 **SERUM RESPONSE FACTOR AS A NOVEL TARGETED THERAPY FOR CASTRATE-RESISTANT PROSTATE CANCER**
Maria Prencipe¹, A O'Neill¹, G O'Hurley², A Fabre³, WM Gallagher⁴, Colm Morrissey⁵, E Kay⁶, W Watson¹
¹UCD School of Medicine, Conway Institute of Biomolecula, University College Dublin, Dublin, ²OncoMark Limited, Nova UCD, Dublin, ³Department of Pathology, St Vincent's University Hospital, Dublin, ⁴UCD School of Biomolecular and Biomedical Science, Conway Institute of Biom, University College Dublin, Dublin, ⁵Department of Urology, University of Washington, Seattle, Washington, ⁶Department of Pathology, RCSI Education and Research Centre, Dublin
- 16.30-17.00 **TRANSLATING NextGen SEQUENCING TO THE CLINIC: TARGETING ACTIONABLE GENES ENRICHED IN BREAST CANCER BRAIN METASTASES**
Damir Vareslija¹, A Fagan¹, N Priedigkeit⁵, E Ward¹, S Purcell¹, L Hudson¹, P O'Halloran³, R Dwyer⁴, M Kerin⁴, P Buckley², M Farrell², S Das⁶, D O'Connor⁶, ADK Hill¹, S Oesterreich⁵, AV Lee⁵, L Young¹
¹Surgery Department, RCSI, Dublin, ²Neuropathology, Beaumont, Dublin, ³Neurosurgery, Beaumont, Dublin, ⁴Clinical Science Institute, NUIG, Galway, ⁵Magee-Women's Research Institute, University of Pittsburgh Cancer Institute, Pittsburgh, ⁶MCT, RCSI, Dublin
- 17.00-18.00: **Special IACR Cancer Researcher Medal Presentation:**
Chair: Professor William Watson
2017 Awardee: Professor William Gallagher

"CANCER (RESEARCH) IN IRELAND: PAST, PRESENT AND FUTURE"
Professor William Gallagher, Director of the UCD Conway Institute
Professor of Cancer Biology, UCD School of Biomolecular & Biomedical Science,
Director of the Irish Cancer Society Collaborative Cancer Research Centre BREAST-PREDICT
- 18.00 **CLOSE OF MEETING**
- 19.00 **GALA DINNER and Awards Presentations**
Venue: Kilkenny Castle